Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Nasuh Buyukkaramikli, Saskia de Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen, Maiwenn Al

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
7 Downloads (Pure)
Original languageEnglish
JournalPharmacoeconomics (Print)
Publication statusPublished - 2018

Cite this